{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T01:33:41Z","timestamp":1760060021110,"version":"build-2065373602"},"reference-count":15,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T00:00:00Z","timestamp":1753660800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and Objectives: Thrombocytopenia and hemolytic anemia are common but non-criteria manifestations of antiphospholipid syndrome (APS). However, their relationship with specific immunological profiles remains poorly characterized. This study aimed to evaluate these hematologic manifestations and identify their serological associations in patients with APS. Materials and Methods: We retrospectively reviewed 346 patients diagnosed with APS. Demographic, clinical, and laboratory characteristics were analyzed. Logistic regression was used to identify risk factors associated with hemolytic anemia. Results: The mean age was 47.1 \u00b1 13.1 years, and 71.7% were female. Thrombocytopenia was present in 34.5%, and hemolytic anemia in 16.5% of patients. Lupus anticoagulant (LAC) was the most common antibody (66.8%). In univariate analysis, hemolytic anemia was significantly associated with LAC positivity (OR 4.216, 95% CI: 2.326\u20137.640, p &lt; 0.001), anticardiolipin IgG (OR 7.170, p = 0.007), triple positivity (OR 3.638, p = 0.002), and diabetes mellitus (OR 2.084, p = 0.007). DIAPS showed a protective trend (OR 0.547, p = 0.002). In multivariate analysis, only LAC remained an independent risk factor for hemolytic anemia (adjusted OR 3.557, 95% CI: 1.355\u20139.335, p = 0.003). Conclusions: LAC positivity is an independent predictor of hemolytic anemia in APS. These findings suggest a distinct immunologic profile among patients with hematologic involvement and highlight the need for further investigation into non-criteria manifestations.<\/jats:p>","DOI":"10.3390\/medicina61081364","type":"journal-article","created":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T14:05:47Z","timestamp":1753711547000},"page":"1364","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Lupus Anticoagulant Positivity as a Risk Marker for Hemolytic Anemia in Patients with APS"],"prefix":"10.3390","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1113-2001","authenticated-orcid":false,"given":"Ji-Hyoun","family":"Kang","sequence":"first","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Chonnam National University Medical School & Hospital, 42 Jebong-ro, Dong-gu, Gwangju 61469, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,7,28]]},"reference":[{"key":"ref_1","first-page":"1290","article-title":"Diagnosis and Management of the Antiphospholipid Syndrome","volume":"379","author":"Garcia","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"102913","DOI":"10.1016\/j.autrev.2021.102913","article-title":"Antiphospholipid antibodies and the risk of autoimmune hemolytic anemia in patients with systemic lupus erythematosus: A systematic review and meta-analysis","volume":"21","author":"Bernardoff","year":"2022","journal-title":"Autoimmun. Rev."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"e069717","DOI":"10.1136\/bmj-2021-069717","article-title":"Antiphospholipid syndrome: Advances in diagnosis, pathogenesis, and management","volume":"380","author":"Knight","year":"2023","journal-title":"BMJ"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s13075-022-02726-9","article-title":"Non-criteria manifestations in primary antiphospholipid syndrome: A French multicenter retrospective cohort study","volume":"24","author":"Guedon","year":"2022","journal-title":"Arthritis Res. Ther."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e002534","DOI":"10.1136\/rmdopen-2022-002534","article-title":"Triple positive profile in antiphospholipid syndrome: Prognosis, relapse and management from a retrospective multicentre study","volume":"9","author":"Laurent","year":"2023","journal-title":"Rmd Open"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.3389\/fimmu.2019.01948","article-title":"Triple Antiphospholipid (aPL) Antibodies Positivity Is Associated with Pregnancy Complications in aPL Carriers: A Multicenter Study on 62 Pregnancies","volume":"10","author":"Lazzaroni","year":"2019","journal-title":"Front Immunol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1182\/blood-2002-02-0441","article-title":"Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: A systematic review of the literature","volume":"101","author":"Galli","year":"2003","journal-title":"Blood"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1538-7836.2006.01753.x","article-title":"International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)","volume":"4","author":"Miyakis","year":"2006","journal-title":"J. Thromb. Haemost."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1002\/art.42624","article-title":"The 2023 ACR\/EULAR Antiphospholipid syndrome Classification Criteria","volume":"75","author":"Medha","year":"2023","journal-title":"Arthritis Rheumatol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1136\/annrheumdis-2022-eular.993","article-title":"Triple Positive Profile in Antiphospholipid Syndrome: Prognosis, Relapse and Management from a Retrospective Multicenter Study","volume":"81","author":"Charlotte","year":"2022","journal-title":"Ann. Rheum. Dis."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"101015","DOI":"10.1016\/j.blre.2022.101015","article-title":"Hematological manifestations of antiphospholipid syndrome: Going beyond thrombosis","volume":"58","author":"Saliba","year":"2023","journal-title":"Blood Rev."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.blre.2008.03.005","article-title":"The hematologic manifestations of the antiphospholipid syndrome","volume":"22","author":"Uthman","year":"2008","journal-title":"Blood Rev."},{"key":"ref_13","first-page":"e95","article-title":"Laboratory diagnosis of the antiphospholipid syndrome: A comparative study of the clot-based lupus anticoagulant test and antiphospholipid antibody assays","volume":"125","author":"Devreese","year":"2010","journal-title":"Thromb. Res."},{"key":"ref_14","first-page":"628","article-title":"Prevalence and clinical significance of non-criteria manifestations of antiphospholipid syndrome: A European multicenter study","volume":"11","author":"Arnaud","year":"2012","journal-title":"Autoimmun. Rev."},{"key":"ref_15","first-page":"369","article-title":"Antiphospholipid syndrome: Challenges ahead","volume":"17","author":"Oku","year":"2014","journal-title":"Int. J. Rheum. Dis."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/61\/8\/1364\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:17:20Z","timestamp":1760033840000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/61\/8\/1364"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,28]]},"references-count":15,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,8]]}},"alternative-id":["medicina61081364"],"URL":"https:\/\/doi.org\/10.3390\/medicina61081364","relation":{},"ISSN":["1648-9144"],"issn-type":[{"type":"electronic","value":"1648-9144"}],"subject":[],"published":{"date-parts":[[2025,7,28]]}}}